Medicare Could Cover Melphalan Regimen For 1000 Stem Cell Procedures
Executive Summary
Medicare could cover treatment for over 1,000 multiple myeloma patients receiving high-dose chemotherapy in combination with autologous stem cell transplantation, under a recommendation by the Drugs, Biologics and Therapeutics Panel of the Medicare Coverage Advisory Committee.
You may also be interested in...
Roche Xeloda To Be Reimbursed By Medicare As Prodrug Of 5-FU
Roche's oral treatment for late-stage metastatic breast cancer Xeloda (capecitabine) will be covered for outpatient use by Medicare effective Jan. 1, 1999, the company announced Jan 13.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials